Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic
Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic
复制标题
DOI：
10.1016/s0304-3835(98)00110-4
复制
发表时间：
1998-09-25
期刊：
影响因子：
9.7
通讯作者：
Hayashi, S
中科院分区：
文献类型：
--
作者：
Yatsunami, J;Tsuruta, N;Hayashi, S
我们研究了罗红霉素，一种14元环大环内酯类抗生素，对肿瘤血管生成的影响，使用小鼠背气囊模型。罗红霉素的抑制作用是剂量依赖性的，100 mg/kg的罗红霉素腹膜内给药，每天两次，减少了密集的毛细血管网面积约为对照组的20%。然而，在高达50 μ M的浓度下，罗红霉素对肺癌细胞和人血管内皮细胞生长以及肺癌细胞产生血管生成诱导因子白细胞介素-8和血管内皮生长因子没有影响。浓度大于20 μ M的罗红霉素抑制内皮细胞迁移和管形成。(C)1998爱思唯尔科学爱尔兰有限公司保留所有权利。
We examined the effects of roxithromycin, a 14-membered ring macrolide antibiotic, on tumor angiogenesis using a mouse dorsal air sac model. The inhibitory effect of roxithromycin was dose-dependent and 100 mg/kg of roxithromycin administered intraperitoneally twice a day reduced the dense capillary network area to about 20% of the control. However, at concentrations of up to 50 mu M, roxithromycin had no effect on lung cancer cells and human vascular endothelial cell growth and lung cancer cell production of the angiogenesis-inducing factors interleukin-8 and vascular endothelial growth factor. Roxithromycin at concentrations greater than 20 mu M inhibited endothelial cell migration and tube formation. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.